Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy by Henry, N L et al.
Lack of association between oestrogen receptor polymorphisms
and change in bone mineral density with tamoxifen therapy












1 and V Stearns
3 for the Consortium on Breast Cancer Pharmacogenomics
investigators
1Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA;
2Division of Clinical Pharmacology,
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA;
3Breast Cancer Program, Sidney Kimmel Comprehensive
Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
BACKGROUND: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal
women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in
oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone.
METHODS: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial.
Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12
months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in
the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months.
RESULTS: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with
chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen
therapy were detected.
CONCLUSION: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.
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As mortality from breast cancer has been decreasing (Peto et al,
2000), delayed complications of therapy for breast cancer are
becoming more apparent. In particular, osteoporosis is of
substantial concern in breast cancer survivors, especially in those
diagnosed while still premenopausal. Chemotherapy may induce
ovarian failure in up to 70% of women (Petrek et al, 2006; Stearns
et al, 2006), and the resulting oestrogen depletion can lead to bone
loss (Saarto et al, 1997). In addition, chemotherapy can have direct
detrimental effects on bone density through an inhibition of bone
proliferation (Lester et al, 2005). It is well recognised that
endocrine therapies for breast cancer can have variable effects
on bone mineral density (BMD), depending on the pharmaceutical
agent and the patient population (Chien and Goss, 2006; Perez
et al, 2006; Coleman et al, 2007; Eastell et al, 2008).
Tamoxifen, a selective oestrogen receptor modulator (SERM),
has been the standard adjuvant hormonal treatment for early-stage
hormone receptor-positive breast cancer for more than two
decades (Osborne, 1998). It has antagonistic effects on breast
tissue, thereby inhibiting the growth of hormone-responsive
tumours. Classically, tamoxifen has been considered to have
oestrogenic effects on bone, and postmenopausal women typically
experience an increase in BMD with tamoxifen therapy (Love et al,
1992; Kristensen et al, 1994; Powles et al, 1996). Conversely,
tamoxifen therapy results in decreased BMD in premenopausal
women, although the reason for this difference remains unclear
(Powles et al, 1996; Sverrisdottir et al, 2004). One hypothesis is that
tamoxifen exerts an effect more as an anti-oestrogen in bone in the
premenopausal population because of the greater amount of
circulating oestrogens compared with postmenopausal women
(Powles et al, 1996).
Tamoxifen, a pro-drug, is converted into more active metabo-
lites by cytochrome (CYP) P450 enzymes, primarily by CYP2D6
(Jin et al, 2005). CYP2D6 is a highly polymorphic gene. Indeed,
more than 80 different alleles have been identified, many of which
confer a decreased or absent CYP2D6 activity. As has been
previously shown in the cohort of patients described in this
report, there is an association between decreased CYP2D6 activity
and decreased serum concentrations of endoxifen, one of the
main active metabolites of tamoxifen (Jin et al, 2005). Data suggest
that women with the CYP2D6 poor metaboliser phenotype have
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sworse breast cancer outcomes, and may have different
tamoxifen-related toxicity profiles compared with women with a
normal CYP2D6 activity (Goetz et al, 2005; Desta and Flockhart,
2007).
Tamoxifen acts via modulation of oestrogen receptors (ER).
Single-nucleotide polymorphisms (SNPs) have been identified in
both ESR1 and ESR2, the genes that encode for ER-a and ER-b,
respectively. These SNPs have been shown to be associated with
breast cancer risk and breast cancer survival, as well as with serum
lipid concentrations in healthy women (Herrington et al, 2002;
Gold et al, 2004; Boyapati et al, 2005). In contrast, numerous
studies have evaluated associations between BMD and ER
genotypes in non-breast cancer patients (Willing et al, 1998;
Ioannidis et al, 2004; Sowers et al, 2004; Gennari et al, 2007), but
these results have been inconsistent. Few results have been
reported that associate ER polymorphisms with a change in
BMD in women treated with SERMs (Yoneda et al, 2002; Heilberg
et al, 2005).
To further analyse the associations between genetic variants in
ESR1, ESR2, and CYP2D6 on BMD, we initiated a prospective study
to evaluate the changes in BMD in both pre- and postmenopausal
women who were recommended tamoxifen either as adjuvant
therapy for newly diagnosed breast cancer or for chemopreven-
tion. Baseline BMD and change in BMD with 1 year of therapy were




Eligible patients were recruited into a prospective, observational,
open-labelled, multicentre registry study conducted by the
Consortium on Breast Cancer Pharmacogenomics (COBRA) from
2000 to 2006. Participating COBRA institutions included the
Lombardi Comprehensive Cancer Center at Georgetown University
Medical Center, Washington, DC; the Indiana University Cancer
Center, Indianapolis, Indiana; and the Breast Oncology Program at
the University of Michigan Comprehensive Cancer Center, Ann
Arbor, Michigan. The analysis presented in this report is a
secondary aim of the main study, and was specifically designed to
test relationships between polymorphisms in the genes that encode
ER and CYP2D6 and change in BMD after 1 year of tamoxifen
therapy. Results from this cohort regarding other genotypes and
phenotypes have been previously reported (Jin et al, 2005, 2008;
Borges et al, 2006; Henry et al, 2009). The study design for this trial
has already been described in detail (Jin et al, 2005) and is listed on
www.ClinicalTrials.gov (NCT0022893).
Pre- and postmenopausal women 18 years or older, who had
oestrogen and/or progesterone receptor-positive breast cancer,
were starting adjuvant treatment with tamoxifen, had a history of
ductal carcinoma in situ, or were at high risk for breast cancer and
starting tamoxifen for chemoprevention were eligible for the study.
Women were ineligible if they were treated with hormone therapy
other than tamoxifen or if they started tamoxifen therapy
concurrently with either radiation therapy or chemotherapy. Other
exclusion criteria included use of concomitant clonidine, bellergal,
megestrol acetate, or chronic corticosteroids (previous intermittent
use of steroids during adjuvant chemotherapy was permitted).
Patients were excluded if they were pregnant or lactating. No
restrictions were placed on the use of bisphosphonates for trial
enrolment, although subjects taking bisphosphonates were
excluded from the BMD analyses, as described below. Use of
supplemental calcium and vitamin D was encouraged. The
protocol was approved by the institutional review boards of all
three participating study sites. All enrolled patients provided
written informed consent.
Study design
Participants with invasive breast cancer or ductal carcinoma in situ
were enrolled in the trial after completion of primary surgical
resection of breast cancer, and after any indicated adjuvant
chemotherapy and/or radiation therapy. Before starting tamoxifen,
a complete medical history, comprehensive list of medications,
physical examination, and baseline laboratory studies were
obtained from each patient. Menopausal status was determined
on the basis of self-reported menstrual history. Women who were
60 years or older, who were amenorrhoeic for 12 months before
enrolment, or had undergone previous bilateral oophorectomy
were considered postmenopausal. Women with regular menses
before adjuvant chemotherapy or tamoxifen were considered
premenopausal. All other patients were considered perimenopau-
sal. Patients were followed up in the outpatient clinic 1, 4, 8, and 12
months after the initiation of treatment with tamoxifen at 20mg
per day. During each follow-up visit, changes in medical history
and medication use were reviewed.
Blood samples (B10ml) were collected at baseline in hepari-
nised Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ,
USA) for plasma isolation and genomic DNA extraction for
genotyping analysis. Plasma was separated within 1h of blood
collection by centrifugation at 2060g. All samples (plasma and
whole blood) were then transferred to cryogenic vials (Corning,
Cambridge, MA, USA) and stored at  801C pending analysis.
Standard dual-energy X-ray absorptiometry (DXA) scans were
performed to measure BMD immediately before initiation of
tamoxifen and at the completion of 1 year of therapy. The BMD
values (calculated in grams per square centimetre) of the left
femoral neck (hip) and total lumbar spine were measured at the
University of Michigan using a Lunar DPX-L bone densitometer
(Madison, WI, USA) and at Indiana University and Georgetown
University using Hologic 4500 bone densitometers (Bedford, MA,
USA). Baseline and 12-month DXA assessments were performed
on the same bone densitometer for all but 17% of subjects at a
single study site (14% of the total population). The BMD data set
can be found on http://www.pharmgkb.org with the accession ID
PS207749.
Genotyping analysis
Genotyping for two ER-a (ESR1) SNPs (XbaI¼rs 9340799 and
PvuII¼rs 2234693) and two ER-b (ESR2) SNPs (ESR2_01¼rs
1256049 and ESR2_02¼rs 4986938) was performed in duplicate by
Taqman assays as previously described by the NCI CGAP project
(snp500cancer.nci.nih.gov). Amplification and analysis were
performed using the iCycler real-time thermocycler (Bio-Rad,
Hercules, CA, USA). Genotyping for CYP2D6 variants was
performed as previously described (Borges et al, 2006). Genotyping
data can be found on the Pharmacogenetics and Pharmacogeno-
mics Knowledge Base website (http://www.pharmgkb.org) with
accession IDs ESR1 (PS204992 and PS204997), ESR2 (PS205000 and
PS203537, PS203538 and PS204999), and CYP2D6 (PS204849,
PS204850, PS204858, PS204859, PS204873, PS204874, PS204875,
PS204901, PS204991, and PS204996).
Statistical analysis
The primary end point for this study was to test the association
between menopausal status, previous chemotherapy, genotype,
and mean percentage change in BMD over 12 months. Because of
similarities in bone biology in peri- and postmenopausal women,
data from peri- and postmenopausal patients were combined and
compared with data from premenopausal patients in this analysis
(Steinberg et al, 1989; Slemenda et al, 1996; Finkelstein et al, 2008).
Analyses were performed on the basis of intention-to-treat,
regardless of compliance with the study drug. Univariate analysis
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swas conducted for all BMD outcomes (hip and lumbar spine BMD
at baseline and the percentage change in BMD from months
0 to 12) to obtain descriptive statistics of variables and study their
underlying distributions. Association between menopausal status,
previous chemotherapy, and other categorical variables with BMD
outcomes was examined using t-tests or ANOVA with post hoc
pairwise comparisons. A general linear model was used to adjust
for age and centre and to assess the interactions between
menopausal status and previous chemotherapy, and was
performed using the SAS program (Cary, NC, USA) (PROC
GLM, SAS v9.1.3). Differences in each BMD outcome among
genotypes, including age- and centre-adjusted analysis, were also
examined using a general linear model. For post hoc comparisons,
we compared the adjusted means between all pairs of three
genotypes while controlling for overall alpha using the Tukey–
Kramer method. For all analyses, a P-value of o0.05 was
considered to be statistically significant.
Our data suggest that the lumbar BMD percentage change from
baseline to 1 year after tamoxifen has an s.d. of 0.06; and 218
samples provide us with 88% power to detect the 1.3% observed
lumbar BMD change. However, we only have 30% power to detect
the 0.4% observed hip BMD change, which has an s.d. of 0.04. The
type I error is set at the 5% level for each test, and they are based
on a one-sample t-test. This pharmacogenetics substudy, which
was a secondary aim of the overall study, was designed to test the
associations between polymorphisms in candidate genes and
change in BMD with 1 year of tamoxifen therapy. Because this
analysis was not the primary aim, however, the power to detect our
observed genetic effect on BMD changes in tamoxifen-treated
patients was o20%.
The ESR1 haplotypes were constructed from ESR1 PvuII and
ESR1 XbaI SNPs using the PHASE2 online software (http://
www.stat.washington.edu/stephens/software.html). The ESR2 hap-
lotypes were also constructed but were few because of the low
frequency of ESR2_01 variants. Haplotype associations with
baseline BMD and percentage change in BMD were tested with a
generalised estimating equation approach through its online




Of the 297 patients who enrolled in the clinical trial, 21 were
excluded from BMD analyses because of concomitant bispho-
sphonate use during the 1-year study duration (n¼17, 5.7%),
significantly outlying values of percentage BMD change (n¼2),
use of raloxifene at the time of study enrolment (n¼1), and failure
to initiate protocol-directed treatment (n¼1) (for CONSORT
diagram see Supplementary Figure 1). All 276 remaining patients
were included in the baseline BMD analyses. Of these 276 patients,
11 did not have any baseline DXA measurements, 3 did not have
baseline lumbar spine DXA measurements, and 9 did not have
baseline hip DXA measurements. Therefore, 95% of analysed
subjects had baseline lumbar spine DXA measurements, and 93%
had baseline hip DXA measurements. Baseline characteristics of
the analysed cohort are described in Table 1. Characteristics of the
21 excluded patients were similar to those of the analysed cohort,
except for the fact that they were significantly older (mean age
63.2, Po0.0001) and all were postmenopausal.
In total, 58 patients did not have matched baseline and
12-month DXA assessments for the following reasons: missing
baseline and/or 12-month measurements at either the hip or the
spine (n¼17), premature discontinuation of study participation
for disease progression (n¼1), toxicity (n¼18), a switch to
aromatase inhibitor (n¼2), relocation (n¼2), non-compliance or
withdrawal of consent (n¼8), and unknown (n¼10). Data on hip
BMD were missing on seven patients at one or both time points
either because of machine malfunction or previous bilateral hip
replacement. Thus, a total of 211 patients (76% of analysed cohort)
had both baseline and 12-month DXA assessment at the hip, and
218 patients (79% of analysed cohort) had both DXA assessments
at the lumbar spine. These subjects are included in the analyses
evaluating percentage change in BMD with 1 year of tamoxifen
therapy. There were no differences between the baseline character-
istics of patients with and without 12-month DXA assessments.
Polymorphisms in genes encoding ER-a (ESR1 PvuII and XbaI)
and ER-b (ESR2_01 and _02) were determined for 260 patients
(Table 2). No genotypes were determined for 16 patients because of
lack of sufficient samples for analysis. A minority of samples were
unable to be genotyped for every gene, as indicated in Table 2. All
genotypes were in Hardy–Weinberg equilibrium. We observed
three possible ESR1 haplotypes on the basis of the ESR1 PvuII and
XbaI genotype: C-A 14.2%, C-G 35.0%, and T-A 50.8%. The three
ESR2 haplotypes based on ESR2_01 and _02 genotypes were A-G
3.8%, G-A 35.5%, and G-G 60.8%.
Baseline BMD
Mean baseline BMD for all patients eligible for analysis divided by
their menopausal and chemotherapy status is listed in Table 3, and
the mean T scores are provided in Supplementary Table 1. Lumbar
spine but not hip BMD was statistically significantly greater in
premenopausal compared with postmenopausal women
(P¼0.032). Similar results were noted for the baseline T score at
the lumbar spine (premenopausal þ0.3, postmenopausal  0.3;
P¼0.003). No statistically significant differences in either the BMD
or T score were noted between subjects treated and not treated
with chemotherapy.
Percentage change in BMD with 1 year of tamoxifen
The percentage change in BMD was calculated for each patient
with matched baseline and 12-month BMD determinations. The
percentage change in hip and lumbar spine BMD for all patients in
aggregate, as well as for patients divided by chemotherapy and/or
menopausal status, is presented in Tables 3 and 4, respectively.
The average change in T score between baseline and 12 months for
patients divided by chemotherapy or menopausal status is given in
Supplementary Table 1.
Similar to previously reported results, postmenopausal women
had an increase in BMD at the hip (þ0.8%) and stability of BMD
at the lumbar spine ( 0.1%) with 1 year of tamoxifen therapy










Mean age (s.d.) 51.9 (10.0) 43.7 (6.5) 56.2 (8.7)
Menopausal status (%) 94 (34.3) 180 (65.7)
Perimenopausal (%) 37 (13.5)
Postmenopausal (%) 143 (52.2)
Weight in kg (s.d.) 76.1 (16.5) 73.5 (17.4) 77.5 (15.9)
Body mass index
b (s.d.) 28.2 (6.3) 27.1 (6.5) 28.8 (6.2)
Chemotherapy
c
Yes (%) 132 (48) 44 (16.1) 88 (32.1)
No (%) 143 (52) 50 (18.2) 92 (33.6)
Abbreviation: BMD¼bone mineral density.
aMenopausal data missing for two
patients.
bHeight missing for 37 patients.
cData missing for one patient.
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s(Love et al, 1992; Kristensen et al, 1994; Powles et al, 1996).
Consistent with earlier reports, BMD decreased at both the hip
( 0.5%) and lumbar spine ( 2.4%) in premenopausal women
(Powles et al, 1996; Sverrisdottir et al, 2004). The percentage
change in BMD at the lumbar spine was statistically significantly
different in premenopausal compared with postmenopausal
women (P¼0.002), but only a trend was noted at the hip
(P¼0.065).
Patients who had received chemotherapy before initiation of
tamoxifen therapy had an increase in both lumbar spine (þ0.5%)
and hip (þ1.3%) BMD, whereas those who did not receive
chemotherapy had a decrease in BMD at both sites ( 2.2 and  0.5%,
Table 2 Characteristics of the analysed SNPs in ESR1 and ESR2 for subjects included in this analysis
SNP dbSNP Location within gene % Allele frequency Genotype frequency Subjects from this analysis
C 0.52 CC 0.245 CC 0.233 (n¼60)
ESR1 PvuII
a rs 2234693 IVS1-397T4C T 0.48 CT 0.549 CT 0.512 (n¼132)
TT 0.206 TT 0.256 (n¼66)
A 0.64 AA 0.462 AA 0.430 (n¼110)
ESR1 XbaI
b rs 9340799 IVS1-351A4G G 0.36 AG 0.355 AG 0.453 (n¼116)
GG 0.183 GG 0.117 (n¼30)
A 0.108 AA 0.020 AA 0.008 (n¼2)
ESR2_01
c rs 1256049 Ex6+32G4A G 0.892 AG 0.176 AG 0.062 (n¼16)
GG 0.804 GG 0.931 (n¼242)
ESR2_02
d rs 4986938 38bp 30 of STP A4G( 3 0UTR) A 0.260 AA 0.088 AA 0.136 (n¼35)
G 0.740 AG 0.343 AG 0.440 (n¼113)
GG 0.569 GG 0.424 (n¼109)
Abbreviation: dbSNP¼single-nucleotide polymorphism database. Allele and genotype frequency data from SNP500Cancer controls (http://snp500cancer.nci.nih.gov/
home_1.cfm).
aData missing for 18 patients.
bData missing for 20 patients.
cData missing for 16 patients.
dData missing for 19 patients.
Table 3 Baseline BMD and change in BMD with 12-month tamoxifen therapy
Time point All patients Premenopausal Postmenopausal Previous chemotherapy No chemotherapy
Lumbar spine
Baseline (gcm
 2) 1.14 (1.12 to 1.16) 1.17 (1.14 to 1.21)
a 1.13 (1.10 to 1.15)
a 1.14 (1.11 to 1.16) 1.15 (1.12 to 1.18)
n¼262 n¼91 n¼171 n¼123 n¼139
% Change at 12 months after tamoxifen  0.9 ( 1.6 to  0.2)  2.4 ( 3.6 to  1.2)
b  0.1 ( 1.0 to 0.7)
b +0.5 ( 0.5 to 1.5)
d  2.2 ( 3.2 to 1.3)
d
n¼218 n¼77 n¼141 n¼105 n¼113
Hip
Baseline (gcm
 2) 0.99 (0.97 to 1.01) 1.00 (0.97 to 1.03) 0.98 (0.96 to 1.01) 0.98 (0.96 to 1.00) 1.00 (0.97 to 1.02)
n¼256 n¼90 n¼166 n¼120 n¼136
% Change at 12 months after tamoxifen 0.4 ( 0.3 to 1.0)  0.5 ( 1.5 to 0.6)
c +0.9 (0.0 to 1.7)
c +1.3 (0.4 to 2.2)
e  0.5 ( 1.5 to 0.4)
e
n¼211 n¼78 n¼133 n¼103 n¼108
Abbreviation: BMD¼bone mineral density. For baseline DXA measurements, the 95% confidence interval of mean BMD is given for all patients in each subgroup. For
percentage change at 12 months, 95% confidence interval of mean percentage change is given for those patients in each subgroup with both baseline and 12-month




Table 4 Baseline and percentage change in BMD by menopausal and chemotherapy status
Lumbar spine Hip
Chemo Premenopausal Postmenopausal Premenopausal Postmenopausal
Baseline (gcm
 2)
Yes 1.166 (1.124 to 1.208) 1.119 (1.083 to 1.156) 1.001 (0.966 to 1.035) 0.968 (0.938 to 0.998)
n¼43 n¼80 n¼42 n¼78
No 1.181 (1.129 to 1.235) 1.134 (1.0978 to 1.170) 1.002 (0.954 to 1.050) 0.996 (0.966 to 1.023)
n¼48 n¼91 n¼48 n¼88
Percentage change
Yes  1.1 ( 2.9 to 0.6)* +1.4 (0.2 to 2.5)* +0.4 ( 1.2 to 2.1) +1.8 (0.7 to 3.0)**
n¼38 n¼67 n¼38 n¼65
No  3.6 ( 5.2 to  2.0)*  1.5 ( 2.7 to  0.3)*  1.3 ( 2.7 to 0.1)  0.1 ( 1.3 to 1.2)**
n¼39 n¼74 n¼40 n¼68
Abbreviation: BMD¼bone mineral density. For baseline DXA measurements, 95% confidence interval of mean BMD is given for all patients in each subgroup. For percentage
change at 12 months, 95% confidence interval of mean percentage change is given for those patients in each subgroup with both baseline and 12-month measurements. P-values
signify comparisons between two means with the same symbol. *Po0.05. **Po0.01.
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srespectively), differences that were statistically significant
(lumbar spine: Po0.001, hip: P¼0.007). The difference in the
percentage change in BMD between chemotherapy-treated and
-untreated subjects remained when patients were subdivided by
menopausal status (Table 4). Differences were statistically
significant for postmenopausal women at both the lumbar spine
(þ1.4 vs  1.5%; Po0.001) and hip (þ1.8 vs  0.1%; P¼0.025),
and for premenopausal women at the hip ( 1.1 vs  3.6%;
P¼0.030) but not at the lumbar spine.
Effect of ER polymorphisms on baseline BMD
We evaluated the associations between two ESR1 (PvuII and XbaI)
and two ESR2 (ESR2_01 and ESR2_02) polymorphisms and
baseline BMD. No association was noted between baseline BMD
in the overall patient cohort or in any patient subgroup for the four
polymorphisms studied (Supplementary Tables 2–5).
Effect of ER polymorphisms on percentage change in BMD
The same ESR1 and ESR2 polymorphisms were evaluated for
association with percentage change in BMD at the lumbar spine
and hip. No statistically significant associations were noted
between percentage change in BMD and single genotypes in any
of the patient subgroups (Supplementary Tables 6–9). Similarly,
no statistically significant association was observed between ESR1
haplotypes and percentage change in BMD.
Effect of CYP2D6 genotype on BMD
Because we previously showed that serum concentrations of
endoxifen, a key active metabolite of tamoxifen, are lower in
patients with CYP2D6 variants associated with decreased or absent
CYP2D6 activity (Jin et al, 2005; Borges et al, 2006), we evaluated
whether there was an association between the CYP2D6 genotype
and percentage change in BMD with 1 year of tamoxifen therapy.
We did not observe a statistically significant association between
the CYP2D6 genotype and either baseline BMD or percentage
change in BMD in tamoxifen-treated patients (data not shown).
DISCUSSION
In this prospective clinical trial of pre- and postmenopausal
women initiating therapy with tamoxifen, the subjects underwent
BMD assessment at baseline and at 1 year to determine the effects
of tamoxifen therapy on change in BMD. Approximately half of the
patients in this trial had previously received chemotherapy, which
was fairly evenly divided between the menopausal groups. Our
data regarding the general effects of tamoxifen as a SERM are
consistent with previously reported results in which premenopau-
sal women have a decrease in BMD with tamoxifen therapy that is
greater at the lumbar spine than at the hip (Powles et al, 1996;
Sverrisdottir et al, 2004), whereas postmenopausal women
experience an increase in BMD that is greater at the hip than at
the lumbar spine (Love et al, 1992; Powles et al, 1996).
In this study, baseline BMD was similar for patients treated with
or without chemotherapy. However, when evaluating the change
with tamoxifen therapy, our data suggest that tamoxifen caused a
greater increase in BMD in women who received previous
chemotherapy compared with those who did not receive
chemotherapy, regardless of menopausal status. This effect does
not seem to have been previously reported in literature.
Although we do not have an explanation for this finding, one
possible hypothesis is that chemotherapy-induced alterations in
either bone metabolism or ovarian function lead to augmentation
of the oestrogenic effects of tamoxifen on bone. Premenopausal
women who develop chemotherapy-induced amenorrhoea have
been shown to have rapid bone loss compared with those who
retain menstrual function (Saarto et al, 1997; Shapiro et al, 2001;
Fuleihan Gel et al, 2005). Some reports have shown no effect of
post-chemotherapy tamoxifen on BMD (Shapiro et al, 2001). In
contrast, others have shown that premenopausal women treated
with chemotherapy, followed by tamoxifen, who continued to
menstruate 3 years after chemotherapy, have increased bone loss
during tamoxifen therapy compared with controls; in contrast,
those who develop chemotherapy-induced amenorrhoea have less
bone loss during tamoxifen therapy (Vehmanen et al, 2006).
Studies in men of a different SERM, raloxifene, also found an
association between increased bone resorption and higher serum
oestrogen levels, and suppressed bone turnover and lower
oestrogen levels (Doran et al, 2001; Uebelhart et al, 2004).
Therefore, only a subset of data in literature supports our
hypothesis. In our patient cohort, we do not have information
regarding recovery of ovarian function and we lack sufficient
serum samples for measurement of oestradiol concentrations to
assess menopausal status. However, the increase in BMD in
chemotherapy-treated patients was noted in both pre- and
postmenopausal women, suggesting that ovarian function recovery
was not the primary cause of the differential effect of tamoxifen on
BMD in chemotherapy-treated vs untreated patients. It is possible
that these findings are an artefact of the small sample size,
although the high level of statistical significance for the overall
population suggests that the effect may be clinically significant.
Given these potential confounding factors, a confirmation of these
findings in another sample set is warranted.
In postmenopausal women who did not receive chemotherapy,
we did not find as great an increase in BMD with tamoxifen
therapy as has previously been reported (Powles et al, 1996). One
possible explanation for this discrepancy is differences in the
earlier usage of hormone replacement therapy, although we cannot
confirm this hypothesis because these data were not collected in
our patient cohort. Another potential confounder is the substan-
tially higher body mass index in our patient cohort (28.8kgm
 2)
compared with that reported by Powles et al (1996)(25.2kgm
 2).
Finally, a third potential source of bias is the replacement of a DXA
machine at one institution during the conduct of this study.
However, the effect of this change on the outcome of the study is
likely to be minimal, as all subjects at that institution had their
baseline DXA scans performed on the same machine, and
only 17% had their baseline and 12-month DXA assessments
performed on different machines. In addition, this may more
closely reflect standard clinical practice, in which patients are
unlikely to undergo serial bone density assessment on the same
machine. Although bone turnover markers could be assessed to
confirm the changes noted on DXA scanning, we unfortunately do
not have sufficient remaining serum or urine samples for this
evaluation.
The main objective of this analysis was to correlate the influence
of inherited polymorphisms in the genes that encode for ER (ESR1
and ESR2) on baseline BMD and change in BMD with tamoxifen
therapy. However, no associations were detected between any of
the four polymorphisms evaluated and either baseline BMD or
change in BMD with tamoxifen therapy, or within ESR1 or ESR2
haplotypes. This finding is consistent with an earlier report of
tamoxifen therapy in postmenopausal Japanese women, in whom
no association was noted between change in BMD and either of the
two ESR1 genotypes (Yoneda et al, 2002). We also found no
association between percentage change in BMD and genotype
variants in CYP2D6, a key enzyme responsible for the conversion
of tamoxifen into an active metabolite.
The paucity of statistically significant associations between ER
genotypes and change in BMD with tamoxifen therapy in this
study may reflect a true lack of association, or may be because of
the heterogeneity and small sample size of the cohort. More than
1000 SNPs have been identified in ESR1, but the functional
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sconsequence of each SNP has not been characterised. Therefore,
we chose to analyse the effects of SNPs that were previously
extensively evaluated and were shown to have functional
importance. However, as only four genotypes were evaluated in
this analysis, a real effect may have been missed. Additional SNPs
in the genes encoding ER, including those identified in recent
genome-wide association studies (Richards et al, 2008; Styrkars-
dottir et al, 2008), will be evaluated in the future when more data
are available regarding the clinical effect of these mutations. In
addition, an evaluation of associations between SNPs in genes
encoding ER co-activators and corepressors and change in BMD is
currently underway (Richter et al, 2007).
Although we did not observe any statistically significant
associations between genetic variability and change in BMD, our
power to detect small associations was quite low (o20%). Thus, it
is possible that small single gene effects are present, but were not
detected. In addition, because of the complexity of gene–gene
interactions, it is possible that no single genotype–phenotype
association is sufficiently strong to be evident, but rather a
combination of genotypes may be required for a meaningful effect.
Given the difficulties with multiple gene comparisons, a cohort of
this size would be insufficient to arrive at meaningful conclusions
if the effect sizes are small. Although it is possible that a
comprehensive haplotype-tagging approach may engender useful
associations, it is clear that no large effect due to these germline
variants, which have previously been shown to influence BMD, is
evident in this study. It is possible that a pathway approach
involving an examination of genetic variants in genes that code for
other elements within the oestrogen signalling pathways may
reveal valuable mechanistic and predictive data, and that a
genome-wide variant analysis might also be useful, but such
examinations are beyond the scope of this study.
In summary, our data are consistent with previously reported
data on the change in BMD with tamoxifen therapy in pre- and
postmenopausal women. No inherited gene variants were found to
be statistically significantly associated with baseline or change in
BMD during tamoxifen therapy. The finding that previous
chemotherapy may influence BMD response to tamoxifen is
provocative and worthy of further study.
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